The MAP kinase-activated protein kinase 2 contains a proline-rich SH3-binding domain

Katrin Engel, Kathrin Plath and Matthias Gaestel*

Max-Delbrück-Center of Molecular Medicine, R.-Rössle-Str. 10, D-13122 Berlin, Germany

Received 14 October 1993

The protein sequence of MAP kinase-activated protein kinase 2 (MAPKAP kinase 2) deduced from mouse cDNA sequence reveals structural features of the enzyme, which could be of importance for its function: a proline-rich SH3-binding domain N-terminal to the catalytic region, a MAP kinase phosphorylation site and a bipartite nuclear targeting sequence located C-terminal to the catalytic region. The catalytic domain itself has the strongest homology to calcium/calmodulin-dependent protein kinase II. Northern blot analysis demonstrates a 3.5 kb MAPKAP kinase 2 transcript which is ubiquitously expressed and, hence, co-expressed with the mRNA of the recently identified substrate Hsp25 in all tissues analysed. However, the functional consequences of the nuclear targeting sequence present in MAPKAP kinase 2 suggest the existence of further substrates for the enzyme in the nucleus.

Protein kinase; MAPKAP kinase 2; Nnuclear targeting sequence; Heat shock protein; Proline-rich SH3-binding domain; cDNA

1. INTRODUCTION

Protein phosphorylation represents a key mechanism of transduction in mitogenic signalling, e.g. by activating MAP kinase via the MAP kinase cascade. MAP kinase-activated protein kinase 2 (MAPKAP kinase 2) has been described as an enzyme which is activated by phosphorylation via MAP kinases [1]. This property of MAPKAP kinase 2 is shared with the 90 kDa ribosomal S6 kinases (RSKs; members of the RSK family are also referred as S6 kinase I and II, ISPK1 or MAPKAP kinase 1) which are also phosphorylated and activated by MAP kinase as a result of mitogenic stimulation [2]. The substrate used for initial purification of MAPKAP kinase 2 was a peptide derived from the N-terminal part of glycogen synthase [1]. The small heat shock proteins (sHsps) have been identified as further substrates. Both, the small heat shock protein from mouse, Hsp25, and from human, Hsp27, have been demonstrated to be phosphorylated very efficiently by MAPKAP kinase 2 in vitro [3] at the same sites which are phosphorylated in vivo [4,5]. It is not clear whether the sHsps are the only physiological substrates of this enzyme and

*Corresponding author. Fax: (49) (30) 9406-3785.

Abbreviations: bp, base pair(s); Hsp25, small mouse heat shock protein; Hsp27, small human heat shock protein; ISPK1, insulin-stimulated protein kinase 1; MAP, mitogen activated protein; MAPKAP kinase, MAP kinase-activated protein kinase; NTS, nuclear targeting sequence; sHsp, small heat shock protein; RACE, rapid amplification of cDNA ends; RSKs, ribosomal S6 kinases, members of this kinase family are also referred as S6 kinase I, S6 kinase II, ISPK1 or MAPKAP kinase 1; SH3, src homology 3. whether phosphorylation of sHsps is the main process relevant for the biological function of this enzyme.

In this paper we describe cloning and sequencing of mouse MAPKAP kinase 2 cDNA resulting in identification of primary structure motifs which may prove to be of important influence on regulation of function and subcellular localisation of MAPKAP kinase 2.

2. EXPERIMENTAL

2.1. Polymerase chain reaction

Degenerate oligonucleotide 5'-GA(TC)GTNAA(AG)CCNGA-(AG)AA(TC)(TC)T-3' and 5'-TCCANGG(AG)TG(AG)TTCAT(AG)-AA-3' derived from the sequence of the tryptic peptides of domains VIb (DVKPENL) and XI (FMNHPWI) [1,6] were used as primers in a PCR reaction with mouse cDNA as template. The fragment amplified was cloned into pUC18 (Sure Clone Ligation Kit, Pharmacia). DNA sequencing was carried out in both directions using doublestrand plasmid and Sequenase 2.0 (US Biochemical Corp.). The deduced amino acid sequence of the fragment was verified to be a part of the MAPKAP kinase 2 sequence by showing identity to the peptides known from rabbit MAPKAP kinase 2 [1]. A hybridisation probe for screening of the cDNA library and northern hybridisation was generated from the cloned PCR fragments by random priming and labelling with [α -³²P]ATP (3000 Ci/ mmol) (Megaprime labelling kit, Amersham).

2.2. cDNA-screening and rapid amplification of cDNA ends (RACE)

A mouse lung cDNA library in gt10 was screened using the PCR fragment as probe. Four different clones were identified and sequenced as described above. Rapid amplification of cDNA ends [7] was carried out using the 5'-AmpliFINDER RACE Kit (Clontech, Palo Alto, CA) and the primers P1 (5'-ATGTGTGGGCACTGGG-AGG-3') and P2 (5'-CGAAGATCCGCAGCACC-3') complementary to the cloned 5' region of the cDNA.

2.3. Northern blot experiments

A mouse Multi Tissue Northern Blot containing 2 g of electro-

FEBS LETTERS

~	TCT	.CCG	بابابا	CAG	act	CCG	ÇÇG	GCG	CCI	TTC	CCC	AGC	CCT	CCA	CCG	CCAG	CCC	;CG(3CC(CAG	CCG	CCG	CCG	CCG	TTC	ccc	CAG	TTC	CAC	90
G	\$	₽	G	Q	Т	₽	₽	A	P	F	₽	8	P	₽	₽	P	Α_	₽	A	۵.	P	₽	₽	₽	F	₽	Q	F	н	30
																		P	x	X	₽	₽	₽	Ψ	X	₽				
										P	х	x	P	P	₽	Ψ	x	P												
															SH	3-b1	ndi	.ng	dor	nai	n									
			~~~											~» -				~~												
																AAGG														180 60
•	r	3	G	Б	~	+	~	r	R	~	+	1	U	U		ĸ	•	1	3	¥	v	-				÷.	<b>N</b> .		•	60
																										-				
GTG	ста	icaa	ATC	TTC	GAC	AAG	AGA	ACC	CAG	CAA	ала	TTC	GCC	CTA	AAG	ATGC	TCC	AG	BAC	rgt	cca	aag	GCG	cac	AGA	GAG	GTG	GAG	CTG	270
v	I,	R	I	F	D	ĸ	R	т	Q	Q	ĸ	F	A	L	ĸ	M	L	Q	D	С	₽	ĸ	A	R	R	E	V	E	L	90
															II											III				
											_														_					
																TATG														360
T	м	ĸ	A	8	Q	C		Ħ	T	v	н Т		v	U	v	Y	E	Į.	L	I	A	G	ĸ	ĸ	C	ь	ъ	Ŧ	v	120
											-	•																		
ATG	GAG	TGT	CTC	GAT	GGT	GGA	GAG	CTC	TTI	AGT	CGA	ATO	CAG	GAC	CGA	GGAG	ACC	AG	GCA!	rtc.	ACA	GAA	AGA	GAG	GCG	TCA	GAG	ATC	ATG	450
м	R,	С	L	D	Ģ	G	E	L	F	8	R	I	Q	D	R	G	D	Q	A	F	T	E	R	E	A	S	E	I	м	150
							V																							
																CACO														540
ĸ	s	ı VIa	G	E	A	I	Q	¥	г	н	8	I	N	I		Ħ	R	D_		K	P	E	<u>N</u>	г	L	¥	T	s	ĸ	180
		VIA																	V II	9										
AGG	ccc	TAA	GCC	ATT	TTG	AAA	CTC	ACT	GAI	TTT	GGC	TTT	GCA	AGG	GAA	ACCA	CCA	GTO	CAC	AC	ICT	TTG	ACC	ACI	CCG	TGT	TAT.	ACA	CCA	630
																Т														210
										VII																				
		GTO																												
1																TGTG														720
	•			P	E											тото С_														720 240
	-				E																									
		v	A	P VI	E II	v	L	G	P	E	ĸ	Y	D	ĸ	S		D	м.	W IX	s K	L	đ	<u>v</u>	I	м	Y	I	L	L	
TGT	GGG	V TAT	<u>A</u>	P VI CCC	E II TTC	V TAT	L	g Aag	P	E	K CTT	Y	D ATC	K TCT	s	с_	D TGA	M	W I)	s K CGT4	L	g CGA	 ATG	I	M	Y TAT	I GAA	L TTT	L	240
TGT	GGG	V TAT	<u>A</u>	P VI CCC	E II TTC	V TAT	L	g Aag	P	E	K CTT	Y	D ATC	K TCT	s	с	D TGA	M	W I)	s K CGT4	L	g CGA	 ATG	I	M	Y TAT	I GAA	L TTT	L	240 810
tgt C	GGG G	V TAT Y		P VI CCC P	E II TTC F	V TAT Y	L TCC S	g AAG K	P CAC H	E GGC G	K CTT L	Y GCC: A	D ATC I	K TCT S	s ccg	с веса в	D TGA M	M ACJ N	W I) ACT( T	S CGT/ R X	L ATT I	g Cga R	ATG	I GGC G	M CAG Q	Y TAT Y	I GAA E	L TTT F	L CCT P	240 810 270
tgt C AAC	666 6 CC6	V TAT Y	A CCC P TGG	P VI CCC P	E II TTC F	V TAT Y GTA	L TCC S TCA	g AAG K GAA	P CAC H GAA	e GGC G	K CTT L	Y GCC: A ATG	D ATC I CTT.	K TCT S ATC	s ccg P cgg	C _ GGCA G	D TGA M	M ACJ N	W I) ACT( T	S CGT/ R X	L ATT I BAG	G CGA R	ATG M	I GGC G	M CAG Q AGA	Y TAT Y ATG	I GAA E ACC	L TTT F ATC	L CCT P	240 810 270 900
tgt C AAC	666 6 CC6	V TAT Y	A CCC P TGG	P VI CCC P	E II TTC F	V TAT Y GTA	L TCC S TCA	g AAG K GAA	P CAC H GAA	e GGC G	K CTT L	Y GCC: A ATG	D ATC I CTT.	K TCT S ATC	s ccg P cgg	с веса в	D TGA M	M ACJ N	W I) ACT( T	S CGT/ R X	L ATT I BAG	G CGA R	ATG M	I GGC G CAG	M CAG Q AGA	Y TAT Y	I GAA E ACC	L TTT F	L CCT P	240 810 270
tgt C AAC	666 6 CC6	V TAT Y	A CCC P TGG	P VI CCC P	E II TTC F	V TAT Y GTA	L TCC S TCA	g AAG K GAA	P CAC H GAA	e GGC G	K CTT L	Y GCC: A ATG	D ATC I CTT.	K TCT S ATC	s ccg P cgg	C _ GGCA G	D TGA M	M ACJ N	W I) ACT( T	S CGT/ R X	L ATT I BAG	G CGA R	ATG M	I GGC G CAG	M CAG Q AGA	Y TAT Y ATG	I GAA E ACC	L TTT F ATC	L CCT P	240 810 270 900
tgt C AAC N	GGG G CCG P	V TAT Y IGAG E	A CCC P TGG W	P VI CCC P TCA	E II F GAA E	V TAT Y GTA V	L S TCA S	G AAG K GAA E	P CAC H GAA B	e ggc g gtg v	K CTT L AAG K	Y GCCI A ATG	D ATC I CTT. L	K TCT S ATC I	S CCG P CGG R	C _ GGCA G AATC N	TGA M TGC L	M ACJ N TAJ	W I) ACTO T	S CGT/ R X X ACA4	L ATT I BAG E	G R R CCC P	ATG M ACC T	I G G CAG Q	M CAG Q AGA <u>R</u> XI	Y TAT Y ATG M	I GAA E ACC. T	L TTT F ATC I	L CCT P ACA T	240 810 270 900 300
tgt C AAC N GAA	GGG G CCG P TTC	V TAT Y GAG E	A CCC P TGG W	P VI CCC P TCA S	E II F GAA E CCC	V TAT Y GTA V TGG	L TCC S TCA S ATC	G AAG K GAA E ATG	P CAC H GAA B CAA	E GGC G GTG V	K CTT L AAG K	Y GCC: A ATG M	D ATC I CTT. L GTC	K TCT S ATC I	S CCG P CGG R CAG	C _ GGCA G N AATC N	D TGA M TGC L	M ACJ N TAJ L	W I) ACTO T	S CGT/ R X X ACA/ T	L ATT I BAG E	G R CGA P CGT	ATG M ACC T	I GGC G CAG Q CTG	M CAG Q AGA R XI XI	TAT Y ATG M GAG	I GAA E ACC T GAC	L TTT F ATC I AAG	L CCT P ACA T	240 810 270 900
tgt C AAC N GAA	GGG G CCG P TTC	V TAT Y GAG E	A CCC P TGG W	P VI CCC P TCA S	E II F GAA E CCC	V TAT Y GTA V TGG	L TCC S TCA S ATC	G AAG K GAA E ATG	P CAC H GAA B CAA	E GGC G GTG V	K CTT L AAG K	Y GCC: A ATG M	D ATC I CTT. L GTC	K TCT S ATC I CCT	S CCG P CGG R CAG	C _ GGCA G AATC N	TGA M TGC L CAC	M ACJ N TAJ L	W I) ACTO T	S CGT/ R X X ACA/ T	L ATT I BAG E	G R CGA P CGT	ATG M ACC T	I GGC G CAG Q CTG	M CAG Q AGA R XI XI	TAT Y ATG M GAG	I GAA E ACC T GAC	L TTT F ATC I AAG	L CCT P ACA T	240 810 270 900 300
tgt C AAC N GAA	GGG G CCG P TTC	V TAT Y GAG E	A CCC P TGG W	P VI CCC P TCA S	E II F GAA E CCC	V TAT Y GTA V TGG	L TCC S TCA S ATC	G AAG K GAA E ATG	P CAC H GAA B CAA	E GGC G GTG V	K CTT L AAG K	Y GCCI A ATG M AAG	D ATC I CTT. L GTC V	K TCT S ATC I CCT P	S CCG P CGG R CGG R	C _ GGCA G AATC N ACTC T	D TGA M TGC L CAC P P	M ACJ N TAJ L TTAJ L	W T) ACTO T AAAJ K	S CGT R X ACAA T ACCA T	L ATT I BAG E S	G CGA R CCCC P CGT R	ATG M ACC T	I GGC G CAG Q CTG	M CAG Q AGA R XI XI	TAT Y ATG M GAG	I GAA E ACC T GAC	L TTT F ATC I AAG	L CCT P ACA T	240 810 270 900 300
tgt C AAC N GAA E	GGG G CCG P TTC F	V TAT Y GAG E CATG M	A CCCC P TGG W AAAC N	P VI CCCC P TCA S CAC	E II F GAA E CCCC P	V TAT Y GTA V TGG	L TCC S TCA S ATC I	G AAG K GAA E ATG M	P CAC H GAA B CAA Q	E G G G G G G G G G G G G G G G G G G G	K CTT L AAG K ACG T	Y GCC: A ATG M AAG K MA:	D ATC I CTT. L GTC V P k	K TCT S ATC I CCT P P	S CCGG P CGGG R CAGG S CAGG S S S S S	GGCA G AATC N ACTC <u>T</u> S/T phos	D TGA M TGC L CAC P P pho	M N TAJ L TTG L	W I) ACTO T K EACJ H H	S K R X ACA4 T ACC4 T	L ATT I BAGC S si	G CGA R CCCC P CGT R te	V ATG M ACC T GTC V	I G G CAG Q CTG L	M CAG Q AGA XI XI XI XI	Y TAT Y ATG M GAG E	I GAA E ACC. T GAC. D	L TTT F ATC I AAG K	L CCT P ACA T GAA E	240 810 270 900 300 990 330
TGT C AAC N GAA E CGA	GGG G CCG P TTC F	V TAT Y GAG E XATG M	A CCCC P TGG W AAAC N	P VI CCCC P TCA S CAC H	E II TTC F GAAA E CCCC P	V TAT Y GTA V TGG W	L TCC S TCA S ATC I GAG	G AAAG K GAAA E ATG M	P CAC E GAA B CAA CAA	E GGGC G GTG V TCT. S	K CTT L AAG K ACG T	Y GCCC A ATG M AAG K MAI	D ATC I CTT. L GTC V P k GCC	K TCT S ATC I CCT <u>P</u> P ina	S CCGG P CGGG R CAG S CAG S CAG S CAG	C _ GGCA G AATC N ACTC <u>T</u> S/T phos	D TGA M TGC L CAC P P pho	M N TAN L TTAN L TTAN L TTAN L TTAN	W I) ACTO T AAAAA K EACJ H Lati	S CGT/ R X ACA4 T T Lon BAG6	L ATT I BAG E S S I CAG	G CGA R CCCC P CGT R te	V ATG M ACC T GTC V	I GGC G CAG Q CTG L	M CAG Q AGA XI XI AAG K	Y TAT Y ATG M GAG E	I GAA E ACC. T GAC. D	L TTT F ATC I AAG K	L CCT P ACA T GAA E	240 810 270 900 300 990 330
TGT C AAC N GAA E CGA	GGG G CCG P TTC F	V TAT Y GAG E XATG M	A CCCC P TGG W AAAC N	P VI CCCC P TCA S CAC H	E II TTC F GAAA E CCCC P	V TAT Y GTA V TGG W	L TCC S TCA S ATC I GAG	G AAAG K GAAA E ATG M	P CAC E GAA B CAA CAA	E GGGC G GTG V TCT. S	K CTT L AAG K ACG T	Y GCCC A ATG M AAG K MAI	D ATC I CTT. L GTC V P k GCC	K TCT S ATC I CCT <u>P</u> P ina	S CCGG P CGGG R CAG S CAG S CAG S CAG	GGCA G AATC N ACTC <u>T</u> S/T phos	D TGA M TGC L CAC P P pho	M N TAN L TTAN L TTAN L TTAN L TTAN	W I) ACTO T AAAAA K EACJ H Lati	S CGT/ R X ACA4 T T Lon BAG6	L ATT I BAG E S S I CAG	G CGA R CCCC P CGT R te	V ATG M ACC T GTC V	I GGC G CAG Q CTG L	M CAG Q AGA XI XI AAG K	Y TAT Y ATG M GAG E AAG	I GAA E ACC. T GAC. D	L TTT F ATC I AAG K	L CCT P ACA T GAA E	240 810 270 900 300 990 330
TGT C AAC N GAA E CGA	GGG G CCG P TTC F	V TAT Y GAG E XATG M	A CCCC P TGG W AAAC N	P VI CCCC P TCA S CAC H	E II TTC F GAAA E CCCC P	V TAT Y GTA V TGG W	L TCC S TCA S ATC I GAG	G AAAG K GAAA E ATG M	P CAC E GAA B CAA CAA	E GGGC G GTG V TCT. S	K CTT L AAG K ACG T	Y GCCC A ATG M AAG K MAI	D ATC I CTT. L GTC V P k GCC	K TCT S ATC I CCT <u>P</u> P ina	S CCGG P CGGG R CAG S CAG S CAG S CAG	C _ GGCA G AATC N ACTC <u>T</u> S/T phos	D TGA M TGC L CAC P P pho	M N TAN L TTAN L TTAN L TTAN L TTAN	W I) ACTO T AAAAA K EACJ H Lati	S CGT/ R X ACA4 T T Lon BAG6	L ATT I BAG E S S I CAG	G CGA R CCCC P CGT R te	V ATG M ACC T GTC V	I GGC G CAG Q CTG L	M CAG Q AGA XI XI AAG K	Y TAT Y ATG M GAG E	I GAA E ACC. T GAC. D	L TTT F ATC I AAG K	L CCT P ACA T GAA E	240 810 270 900 300 990 330
TGT C AAC N GAA E CGA R	GGG G P TTC F	V TAT Y GAG E ATG M GAG E	A CCCC P TGG W AAAC N GAT	P VI CCCC P TCA S CACC H GTC. V	E II TTC F GAA E CCC P	V TAT Y GTA V TGG W GAG E	L TCC S TCA S ATC I GAG	G AAG K GAA E ATG M ATG M	P CAC E GAA B CAA S CAA Q ACC T	E GGGC G GTG V TCT. S	K CTT L AAG K ACG T GCC A	Y GCCC A AATG M AAGG K MA: TTG L	D ATC I CTT. L GTC V P k GCC A	K TCT S ATC I P P ina ACG T	S CCGG P CGGG R CAG S CAG S CAG N	C GGCA G AAATCC N ACTCC <u>T</u> S/T Phose CGTG R	D TGA M TGC L CAC P P pho V	M N TAM L TTGK L D TTGK L D	W I) ACT( T AAAA) K EACJ H Lat: TAT( Y	S K R X ACA4 T Lon BAG4 E	L ATT I BAGC S Si CAG	G CGA R CCCC P CGT R te ATC I	V ATG M ACC T GTC V AAG K	I GGC G CAG Q CTG L ATA I	M CAG Q AGA R XI AAG K NT	Y TAT Y ATG M GAG E AAG K S1	I GAA E ACC. T GAC. D ATA I	L TTT F ATC I AAG K GAA E	L CCT P ACA T GAA E GAA D	240 810 270 900 300 990 330
TGT C AAC N GAAA E CGAA R CGAA	GGG G CCG P TTC F TGG W	V TAT Y GAG E ATG M KGAG E	A CCCC P TGG W AAAC N GAT D	P VI CCCC P TCA S CACC H GTC. V	E II TTC F GAAA E CCCC P AAAG K CTT	V TAT Y GTA V TGG W GAG E CTC	L TCC S TCA S ATC I GAG E	G AAG K GAA E ATG M ATG	P CAC E GAA B CAA B CAA C CAA C CAA C CAC CGG	E GGC G GTG V TCT. S CAGT S	K CTT L AAG K ACG T GCC A	Y GCCL A AAGG K MA: TTGG L GCT	D ATC I CTT. L GTC V P k GCC A	K TCT S ATC I CCT <u>P</u> P ina ACG T	S CCGG P CGGG R CAG CAG S S CAG S CAG S CAG S CAG CAG C G TG	C GGCA G AAATCC N ACTCC <u>T</u> S/T Phose CGTG R	D TGA M TGC L CAC P P P Pho V TTG V	M N TTAJ L TTGK L D TTGK D D NCGK	W I) ACT( T AAAA) K EAC) H Iat: TAT( Y SCT(	S K CGTJ R X X ACA4 T T Lon BAG4 E	L ATT I BAGC S Si CAG Q BCC	G CGA R CCCC P CGT R te ATC I CAC	V ATG M ACC T GTC V XAAG K TGA	I GGC G CAG Q CTG L ATA I GCC	M CAG Q AGA R XI AAG K NT	Y TAT Y ATG M GAG E AAG K S1	I GAA E ACC. T GAC. D ATA I	L TTT F ATC I AAG K GAA E	L CCT P ACA T GAA E GAA D	240 810 270 900 300 990 330 1080 360
TGT C AAC N GAAA E CGAA R CGAA	GGG G CCG P TTC F TGG W	V TAT Y GAG E ATG M KGAG E	A CCCC P TGG W AAAC N GAT D	P VI CCCC P TCA S CACC H GTC. V	E II TTC F GAAA E CCCC P AAAG K CTT	V TAT Y GTA V TGG W GAG E CTC	L TCC S TCA S ATC I GAG E	G AAG K GAA E ATG M ATG	P CAC H GAA B CAA S CAA CAA C CAA C CAC C CGG R	E GGC G GTG V TCT. S CAGT S	K CTT L AAG K ACG T GCC A	Y GCCL A AAGG K MA: TTGG L GCT	D ATC I CTT. L GTC V P k GCC A	K TCT S ATC I CCT <u>P</u> P ina ACG T	S CCGG P CGGG R CAG CAG S S CAG S CAG S CAG S CAG CAG C G TG	C GGCA G AATCO N ACTOC T S/T Phose COTG R GAGG	D TGA M TGC L CAC P P P Pho V TTG V	M N TTAJ L TTGK L D TTGK D D NCGK	W I) ACT( T AAAA) K EAC) H Iat: TAT( Y SCT(	S K CGTJ R X X ACA4 T T Lon BAG4 E	L ATT I BAGC S Si CAG Q BCC	G CGA R CCCC P CGT R te ATC I CAC	V ATG M ACC T GTC V XAAG K TGA	I GGC G CAG Q CTG L ATA I GCC	M CAG Q AGA R XI AAG K NT	Y TAT Y ATG M GAG E AAG K S1	I GAA E ACC. T GAC. D ATA I	L TTT F ATC I AAG K GAA E	L CCT P ACA T GAA E GAA D	240 810 270 900 300 990 330 1080 360 1170

Fig. 1. cDNA sequence and deduced protein structure of MAPKAP kinase 2. The stop codon and polyadenylation signal are underlined. The protein sequence of MAPKAP kinase 2 deduced from the open reading frame is shown in one letter code. The proline-rich SH3-binding domain, the MAP kinase phosphorylation site and the bipartite nuclear targeting sequence are underlined, the consensus sequence for the SH3-binding domain and the MAP kinase recognition motif are given in italics and aligned to the sequence. The bipartite nuclear targeting sequence is indicated by NTS1 and NTS2. The protein kinase catalytic domain sequence motifs (I–XI) are marked and the highly conserved amino acid residues of these motifs are underlined.

phoretically separated poly(A)⁺ mRNA from each tissue was obtained from Clontech (Palo Alto, CA). Probes used were the MAPKAP kinase 2 PCR fragment, an about 600 bp *Hin*dIII cDNA fragment of Hsp25 [8] and a 2 kb probe for human  $\beta$ -actin. Hybridisation was carried out in 5 × SSPE, 10 × Denhardt's reagent, 2% SDS, 50  $\mu$ g/ml fragmented salmon sperm DNA, 50% formamide at 42°C overnight. Filters were washed three times for 10 min in 2 × SSC, 0.05% SDS at 50°C. Northern blot analysis and quantification was performed using the Bio Imaging analyser BAS 2000 (Fuji).

## 3. RESULTS

# 3.1. cDNA and deduced protein sequence of MAPKAP kinase 2

Two degenerate oligonucleotides were derived from the sequence of tryptic peptides of the catalytic domain motifs VIb and XI of rabbit MAPKAP kinase 2 [1]. The oligonucleotides were used to amplify a 418 bp mouse cDNA fragment of MAPKAP kinase 2, which was further taken as probe for screening of a mouse lung cDNA library in  $\lambda$ gt10. Four different types of overlap-

December 1993

ping cDNA clones were isolated and analysed. All clones obtained lack the part corresponding to the extreme 5'-end of the MAPKAP kinase 2-mRNA and the translation start site. Further screening of the cDNA library and RACE did not provide cDNA clones which code for the translation start of MAPKAP kinase 2. This is probably a result of the extremly GC-rich region at the 5'-end of the mRNA sequence, which may produce stable secondary mRNA structure and thereby inhibits full-length first strand cDNA synthesis [7]. Similar problems caused by 5' GC-rich regions have been described in cloning for the MAP kinase erk-1 cDNA [9]. The cDNA sequence and translated protein sequence of MAPKAP kinase 2 is shown in Fig. 1. The cDNA sequence represents an open reading frame of 1149 bp, coding for a polypeptide of 383 amino acids. It contains a stop codon and a polyadenylation signal AATATA 21 bp upstream of the poly(A) tail in the 3'non-translated region. The deduced protein sequence of MAPKAP kinase 2 shows two overlapping proline-rich SH3-binding domains with the sequence PFPAPPPP-APAQPPPPFP N-terminal to the catalytic domain of the kinase. At least one of these overlapping motifs perfectly matches the SH3-binding consensus sequence  $PXXPPP\psi XP$  ( $\psi$  represents a hydrophobic amino acid residue) [10]. The catalytic domain of MAPKAP kinase 2 is characterised by the various conserved motifs (I-XI, cf. [6]) as well as by the occurrence of the sequences of the tryptic peptides obtained form rabbit MAPKAP kinase 2 [1]. The MAP kinase phosphorylation site in rabbit MAPKAP kinase 2 has already been identified [1]. In the deduced amino acid sequence of mouse MAPKAP kinase 2 this site is located C-terminal to the catalytic domain within the sequence motif POT*P. which is in agreement with the MAP kinase recognition motif PXS/TP [11]. This finding is in contrast to the position of the phosphorylation sites of other protein kinases as ISPK1 (RSK, MAPKAP kinase 1) [12], cAMP-dependent protein kinase [13], MAP kinase [14] and p34cdc2 kinase [15], which are located within the catalytic domain N-terminal to the motif VIII [6]. Interestingly, the phosphorylation site of MAPKAP kinase 2 is followed by an ideal bipartite nuclear targeting signal KK(X)₁₀KRRKK, which has been described to be sufficient for nuclear localisation of a variety of proteins [16].

#### 3.2. Homology to other protein kinases

The primary structure of the catalytic domain of MAPKAP kinase 2 was compared to the other protein kinases contained in the Protein Kinase Catalytic Domain Database (cf. [6]) using the method of Needleman and Wunsch [17]. The sequence of highest homology is the a  $\alpha$  subunit of rat calcium/calmodulin-dependent protein kinase II (score 50.8) followed by myosin light chain kinase from chicken smooth muscle (score 30.8). the C-terminal catalytic domain of mouse RSK kinase

	I.I.	II	III	
MK2		* LRIFDKRTQQKFALKMLQD	*	
CAMIIA		RcvkvlagQeYAaKiint		47
MLCK M	Yni-eErlGsGkfGdV	<b>RlveKKT</b> gkvw <b>A</b> gKffka	KKISaNDhqKberea	49 47
RSK1 C	YvVk-Et i GvGsvsvcl	(RcvhKaTnmeYAvKvidk	greanskeniidei	45
PSK H1		RVehRaTrOpYA1KM1Et		45
		<b></b>	Allegrand cocr	
	IV		V	
MK2	D) COODUNITIES	VYENLYAGRKCLLIVMECI	*	
CAMII A	ricellybentyribe	sisEeghhyLIFDLv	DGGELFSRIQDRGDQ	94 93
MLCK M	simnclHhPklVOcVD	FEEKanivmVLEMv	COULTEDIVARE	93
RSK1 C		YDDgkhvyLvteLM		87
PSK H1	rvlRrvrhaNIIOlVey	/FEtqeRvyMvmeLa	tGCELfdBI aKG	91
-	-	4 4		51
	VIa	VIb		
		* * *		
MK2		IQYLHSINIAHRDVKPEN		143
CAMILA	yYSEADAShciqqIlEA	WlhcHqmgVvHRD1KPEN	LLlaSKlkgaa-vKL	142
MLCK_M		VEY1HkqgIvHLD1KPEN		140
RSK1_C		VEYLHSqgVvHRD1KPsN		137
PSK_H1	SFTERDATrVLqMVIDg	<b>VrYLH</b> algItHRD1KPEN	LLYyhpgtDsk-111	140
	VII	VIII	IX	
MK2	* *	**	* *	
CAMIIA.		TTPCYTPYYVAPEVLGPE		191
MLCK M	aDFGIAIEvegeqqawi	gfa-gTPgYlsPEVLrkD	prgKpvDLWacGVIL	191
RSK1 C	CDECENKOLE-concil	kvlfg <b>TP</b> e <b>FVAPEV</b> iny <b>E</b> MTPCYTanFVAPEVLkrQ	pigyetDMWSiGVic	188
PSK H1		KTTCgTPeYIAPEVLyrk		186
	IDE GIRGAI ANGUUCIP	INTIGGTPETIMPEVILVI K	prenavonwalovia	190
		х		
MK2	VIIICOVDEVENUOT	ISPGMNTRIRMGQYEFPN	*****	
CAMII A	VILLUCYPPI SANGLA	dqhrLyqqIKaGaYDFPs	PEWSEVSEEVKMLIR	241
MLCK M	YTLUSGISPErga	IndnetlanVtsatwtFdD	estdripsakatin	237 234
RSK1 C	YTMLaGYt PFanons-d	tpee11TRIgsGkFt1sg	anwatuert avalue	234
PSK H1	YILLsGtmPFedd	inrtrLyrqIlrGkYsYsg	enWneVSplaKdfid	235
		***************************************	epaps, surgaring	230
	XI *			
MK2	NLLKTEPTORMTITEF	NHPWI 263		
CAMII A	kMLtinPSkRiTaaEaL			
MLCK M	NLLKkDmksRLncTQcL			
RSK1 C	kMLhvDPhQRLTakQvL			
PSK H1	rLLtvDPgaRMTalQaL			
	-			

Fig. 2. Comparison of MAPKAP kinase 2 catalytic domain with catalytic domains of similar proteins kinases. MK2 = mouse MAPKAP kinase 2; CAMII_A =  $\alpha$  subunit of rat calcium/calmodulin-dependent protein kinase II; MLCK_M = myosin light chain kinase from chicken smooth muscle;  $RSK1_C = C$ -terminal catalytic domain of mouse RSK kinase and PSK_H1 = putative protein-serine kinase PSK H1 from HeLa cells. Identities and strong similarities (Y = F, Q = E, V = I, M = L, R = K, D = E, S = T, N = E, H = Q,N = H) to MAPKAP kinase 2 are shown by uppercase letters. The subdomains I to XI (cf. [6]) are indicated and the conserved amino acid

residues of these domains are marked with an asterisk.

(score 27.8) and the putative protein-serine kinase cells PSK H1 from HeLa (score 27.8). The alignment of the catalytic domains of these kinases to MAPKAP kinase 2 is shown in Fig. 2. Interestingly, the homologous kinases are exclusively located in a cluster of the phylogenetic kinase tree known to contain calcium/calmodulin-dependent protein kinases. However, until now no calcium/calmodulin dependence of the MAPKAP kinase 2 [1] and other members of this cluster as RSK C1, RSK C2 and PSK H1 has been observed [6].

#### 3.3. Co-expression of MAPKAP kinase 2 and Hsp25

Northern blot experiments revealed an about 3.5 kb mRNA for mouse MAPKAP kinase 2 (Fig. 3). The large size of the MAPKAP kinase 2-mRNA cannot be explained by the coding and 3' non-translated region analysed and is probably the result of the size of the 5' non-translated region. In all mouse tissues under investigation expression of MAPKAP kinase 2 could be detected. Using specific DNA probes we have also monitored expression of the MAPKAP kinase 2 substrate






Fig. 3. Northern blot analysis of expression of MAPKAP kinase 2 and Hsp25. Expression of Hsp25-mRNA (a), MAPKAP kinase 2-mRNA (b) and  $\beta$ -actin-mRNA (c) in different mouse tissues.

Hsp25 and as a control the expression of  $\beta$ -actin. The relative amount of specific MAPKAP kinase 2-mRNA and Hsp25-mRNA compared to the  $\beta$ -actin signal was quantitatively analysed by phospho-imaging and is shown in Table I. Interestingly, the lowest expression of both MAPKAP kinase 2-mRNA and Hsp25-mRNA compared to  $\beta$ -actin-mRNA is detected in liver, kidney and brain. The highest relative expression of enzyme and substrate-mRNA is calculated for spleen, caused by relatively low abundant  $\beta$ -actin-mRNA. A high relative expression of MAPKAP kinase 2- and Hsp25-mRNA is also detected in lung and testis, followed by heart and muscle.

### 4. DISCUSSION

To our knowledge, MAPKAP kinase 2 is the first protein kinase which contains a proline-rich SH3 domain-binding sequence motif. This motif has been identified in different proteins, e.g. formins, muscarinic acetylcholine receptor [10] and *Drosophila* Sos [18]. The src

homology 3 (SH3) domain binding to the proline-rich sequence is present in a variety of molecules involved in signal transduction, as the family of SH3-SH2-adaptors including vav [19] and Drosophila drk [20], the tyrosine kinase oncogenes c-abl and c-src [21] as well as phospholipase  $C\gamma$ , phosphatidyl inositol-3-kinase and GTPase activating protein GAP (for review see [22]). Furthermore, SH3 domains are also found in proteins involved in cytoskeletal architecture as spectrin and actin-binding proteins (see [22]). The presence of a proline-rich SH3 domain-binding motif in MAPKAP kinase 2, which is located at a relatively late position in the mitogenic signal transduction pathway, opens up new possibilities in feedback control of signalling or in further signal transduction influencing cytoskeletal organisation. The identification and characterisation of SH3 domain containing target proteins which bind to MAPKAP kinase 2 will probably provide better understanding of these processes.

The MAPKAP kinase 2-mRNA is demonstrated to be ubiquitously expressed in the various mouse tissues used for the Northern blot analysis. Since Hsp25mRNA is also constitutively expressed in these tissues, a co-expression of MAPKAP kinase 2 and the substrate Hsp25 can be demonstrated (cf. Table I). However, this result does not exclude that both proteins are localised in different cellular compartments. The ideal bipartite NTS motif in the C-terminal region of MAPKAP kinase 2 raises the question of functional significance of this motif. Taking into account the ideal fit of the MAPKAP kinase 2 sequence motif with the NTS consensus sequence and that degenerated NTS motifs are present only in 4.2% of the non-nuclear protein sequences contained in the SwissProt Database [16], it is most likely that this motif is responsible for nuclear localisation of MAPKAP kinase 2. Furthermore, the close proximity of the MAP kinase phosphorylation site, threonine-317, to the bipartite NTS (lysine-356 to lysine-372) raise the possibility of modulation of nuclear targeting activity of MAPKAP kinase 2 by phosphorylation [23]. As demonstrated for the simian virus 40 large T-antigen, nuclear transport kinetics is increased after phosphorylation at sequences flanking the NTS [24]. Accordingly, it could be speculated that activation of MAPKAP kinase 2 via phosphorylation by MAP kinase also modulates its cellular localisation by increasing translocation to the nu-

			Table I				
Relative level of	expression o	of MAPKAP ki	nase 2 (MK2	2) and Hsp25 mRNA	A in different	mouse tissues	3

	Heart	Brain	Spleen	Lung	Liver	Muscle	Kidney	Testis
Hsp25	3.1	0.4	5.5	5.2	0.3	3.7	0.5	5.2
MK2	0.5	0.15	3.6	1.0	0.2	0.8	0.2	1.0

Hybridisation signal was quantified by phospho-imaging and normalised by the signal obtained with the  $\beta$ -actin probe.

cleus. This hypothesis would be parallel to the observation that a fraction of MAP kinases and RSKs enters the nucleus after phosphorylation [25], indicating a general mechanism for transduction of mitogenic signals to the nucleus.

In any case, nuclear localisation of MAPKAP kinase 2 would favour also nuclear substrates, e.g. transcription factors which are phosphorylated in response to mitogenic signals. In contrast, the substrates identified so far, glycogen synthase [1] and the small heat shock proteins [3] are localised in the cytosol. A translocation of the sHsps to the nuclear region has been described as a result of heat shock [26] but not as the result of mitogenic stimulation. Furthermore, after heat shock no significant differences in the degree of phosphorylation of sHsps in the cytosol and in the nuclear fraction could be demonstrated [27,28]. These data could be explained by a cytosolic activity of MAPKAP kinase 2. The analysis of the intracellular localisation of MAPKAP kinase 2 in dependence on its degree of phosphorylation should provide further inside into these questions.

Acknowledgements: We would like to thank Dr. W. Schmidt, MDC Berlin, for support in homology analysis of the catalytic protein kinase regions. The skilled technical assistance of Mrs. G. Schwedersky is acknowledged. This work was supported by the Deutsche Forschungsgemeinschaft (Ga 453/2–1) and by Grant 0310172A from the Bundesministerium für Forschung und Technologie.

#### REFERENCES

- Stokoe, D., Campbell, D.G., Nakielny, S., Hidaka, H., Leevers, S.J., Marshall, C. and Cohen, P. (1992) EMBO J.11, 3985–3994.
- [2] Erikson, R.L. (1991) J. Biol. Chem. 266, 6007-6010.
- [3] Stokoe, D., Engel, K., Campbell, D.G., Cohen, P. and Gaestel, M. (1992) FEBS Lett. 313, 307-313.
- [4] Gaestel, M., Schroder, W., Benndorf, R., Lippmann, C., Buchner, K., Hucho, F., Erdmann, V.A. and Bielka, H. (1991) J. Biol. Chem. 266, 14721–14724.
- [5] Landry, J., Lambert, H., Zhou, M., Lavoie, J.N., Hickey, E., Weber, L.A. and Anderson, C.W. (1992) J. Biol. Chem. 267, 794–803.
- [6] Hanks, S.K. and Quinn, A.M. (1991) Methods Enzymol. 200, 38-62.

- [7] Frohman, M.A., Dush, M.K. and Martin, G.R. (1988) Proc. Natl. Acad. Sci. USA 85, 8998–9002.
- [8] Gaestel, M., Gross, B., Benndorf, R., Strauss, M., Schunk, W.H., Kraft, R., Otto, A., Bohm, H., Stahl, J., Drabsch, H. et al. (1989) Eur. J. Biochem. 179, 209–213.
- [9] Tanner, B. and Mueckler, M. (1993) Biochim. Biophys. Acta 1171, 319–320.
- [10] Ren, R., Mayer, B.J., Cicchetti, P. and Baltimore, D. (1993) Science 259, 1157–1161.
- [11] Alvarez, E., Northwood, I.C., Gonzalez, F.A., Latour, D.A., Seth, A., Abate, C., Curran, T. and Davis, R.J. (1991) J. Biol. Chem. 266, 15277-15285.
- [12] Sutherland, C., Campell, D.G. and Cohen, P. (1993) Eur. J. Biochem. 212, 581-588.
- [13] Shoji, S., Titani, K., Demaille, J.G. and Fisher, E.H. (1979) J. Biol. Chem. 254, 211.
- [14] Payne, D.M., Rossomando, A.J., Martino, P., Erickson, A.K., Her, J.H., Shabanowitz, J., Hunt, D.F., Weber, M.J. and Sturgill, T.W. (1991) EMBO J. 10, 885–892.
- [15] Gould, K.L., Moreno, S., Owen, D.J., Sazer, D.J. and Nurse, P. (1991) EMBO J. 10, 3297–3309.
- [16] Dingwall, C. and Laskey, R.A. (1991) Trends Biochem. Sci. 16, 478-481.
- [17] Needleman, S.B. and Wunsch, C.D. (1970) J. Mol. Biol. 48, 443–453.
- [18] Rogge, R.D., Karlovich, C.A. and Banerjee, U. (1991) Cell 64, 39–48.
- [19] Hu, P., Margolis, B. and Schlessinger, J. (1993) Bioessays 15, 179–183.
- [20] Olivier, J.P., Raabe, T., Henkemeyer, M., Dickson, B., Mbamalu, G., Margolis, B., Schlessinger, J., Hafen, E. and Pawson, T. (1993) Cell 73, 179–191.
- [21] Cicchetti, P., Mayer, B.J., Thiel, G. and Baltimore, D. (1992) Science 257, 803–806.
- [22] Musacchio, A., Gibson, T., Lehto, V.P. and Saraste, M. (1992) FEBS Lett. 307, 55-61.
- [23] Robbins, J., Dilworth, S.M., Laskey, R.A. and Dingwall, C. (1991) Cell 64, 615–623.
- [24] Rihs, H.-P. and Peters, R. (1989) EMBO J. 8, 1479-1484.
- [25] Chen, R.-H., Sarnecki, C. and Blenis, J. (1992) Mol.Cell.Biol. 12, 915–927.
- [26] Arrigo, A.P., Suhan, J.P. and Welch, W.J. (1988) Mol. Cell Biol. 8, 5059–5071.
- [27] Kim, Y.-J., Shuman, J., Sette, M. and Przybyla, A. (1984) Mol. Cell. Biol. 4, 468–474.
- [28] Lee, Y.J., Hou, Z.Z., Curetty, L., Borrelli, M.J. and Corry, P.M. (1990) J. Cell Physiol 145, 324–332.